Objective: Although the primitive haematopoietic and neuronal stem cell marker CD133 is known to be present in cancer stem cells in breast carcinoma, the prognostic impact of CD133 in breast cancer patients remains limited. Materials and Methods: The expression of CD133 protein was analysed by immunohistochemistry in 96 breast cancer specimens and the association of CD133 expression with clinicopathological characteristics, tumour recurrence and survival of the patients was evaluated. Results: Immunohistochemical analysis of 96 breast cancer tissue specimens revealed that CD133 positive tumour cells were frequently present in breast cancer. Increased CD133 immunostaining was found in 41.3%. Increased CD133 expression levels were correlated with increased tumour grade. Kaplan–Meier analysis indicated that patients with increased CD133 levels had shorter overall survival and higher recurrence rates compared with patients with low CD133 expression. Multivariate analyses revealed that increased CD133 expression was an independent prognostic factor for survival and tumour recurrence in patients with breast cancer. Conclusion: These findings suggest that reactivated CD133 positive cells are frequently present in breast cancer. Additionally, increased CD133 expression corresponds with higher grade tumors in breast cancer , thus indicating a poor prognosis for patients.